Why so many people are developing non-alcoholic fatty liver disease

And how it can be reversed

For most people, steatosis (fat accumulation in the liver) from NAFLD is highly responsive to metabolic improvements and can often return to normal with sustained changes in nutrition, movement, and metabolic health when caught early. The liver is a highly resilient organ with a remarkable ability to regenerate when the underlying metabolic stress is reduced. Even in later stages, meaningful improvement remains possible with appropriate changes. In this article, I dive into the physiology of this diagnosis and offer easy and accessible options for intervention.

A Non-Alcoholic Fatty Liver Disease (NAFLD) diagnosis is becoming much more commonplace, and current estimates indicate around 30% (and rising) of the global population lives with it. Some experts believe the actual rate is even higher because most people have no symptoms and aren’t screened until something shows up on routine labs.

This makes NAFLD more common than type 2 diabetes, more common than cardiovascular disease, and far more common than most cancers.

The numbers are rising quickly because the metabolic landscape around us has changed: more ultra-processed foods, more sedentary lifestyles, higher and more chronic stress loads, disrupted sleep, environmental exposures, and a mismatch between how our biology evolved and how we now live.

The link between this landscape and our liver is why NAFLD was re-coined as MASLD (Metabolic-dysfunction Associated Steatotic Liver Disease). It is not simply a ‘liver problem’ in isolation. It is better understood as a whole-body metabolic imbalance that expresses itself in the liver. And the encouraging part is this: metabolic function is highly influenceable.

The information that follows is in no way a substitute for medical care.

To appreciate why MASLD forms, and more importantly, where we have leverage to influence it, we need to look at the physiology. Let’s outline the key metabolic processes involved, starting with lipid (fat) handling and mitochondrial function, inflammation, then the gut-liver axis. So many things come back to the gut!

Physiology and etiology of MASLD

MASLD develops when the liver receives more energy substrates than it can process or export. Liver cells will begin accumulating triglycerides from three main sources: dietary fat, free fatty acids (FFAs) released from insulin-resistant fat tissue, and de novo lipogenesis: the liver’s internal production of fat from excess carbohydrates (particularly fructose).

When insulin resistance develops systemically, fat tissue continues releasing fatty acids even in the ‘fed’ state. Skeletal muscle, which usually serves as the primary metabolic buffer, becomes less able to take up and oxidize glucose and fatty acids, redirecting excess substrates toward the liver. This nutrient overload sets the stage for a condition called steatosis.

Compounding the issue is chronic low-grade inflammation that occurs when dysfunctional fat tissue releases inflammatory cytokines. These cytokines interfere with insulin receptor signaling inside liver cells. When insulin signaling falters, the liver increases fat production and decreases fat oxidation, a combination that accelerates lipid accumulation.

Together, these processes create a metabolic loop: excess substrate delivery → impaired insulin signaling → increased fat storage → further insulin resistance.

Mitochondrial dysfunction as a central driver

Healthy mitochondria metabolize fatty acids through β-oxidation and generate energy through oxidative phosphorylation. In MASLD, the system becomes overloaded.

Mitochondria begin producing excess reactive oxygen species (ROS), unstable oxygen molecules that damage proteins, lipids, and mitochondrial DNA. Over time, mitochondria undergo structural changes, including increased mitochondrial fission, the stress-induced fragmentation of our mitochondrial network. When fission outpaces mitochondrial fusion and mitophagy (the removal of damaged mitochondria), dysfunctional mitochondria begin to accumulate.

This reduces the cell’s ability to oxidize incoming fatty acids, forcing more lipids into storage and increasing vulnerability to oxidative damage. Eventually, mitochondrial strain shifts from adaptive to pathological, acting as a major driver of the progression from simple steatosis to steatohepatitis and fibrosis.

Oxidative stress and liver cell injury

While simple triglyceride storage can be relatively inert, certain lipid species are directly toxic to hepatocytes. Ceramides, diacylglycerols, and other lipotoxic intermediates impair insulin receptor signaling, activate the cell’s emergency response system, and promote apoptosis. Polyunsaturated fatty acids can undergo peroxidation under oxidative conditions, generating reactive aldehydes that cross-link proteins and damage both mitochondrial and cellular membranes.

Cumulatively, these processes promote inflammatory cascades, alter nuclear gene expression, and contribute to fibrosis. Although not all MASLD cases progress to advanced disease, evidence suggests that liver cell injury begins early, driven by oxidative stress and mitochondrial imbalance. These lipotoxic pathways create an environment in which liver cells are increasingly vulnerable to further injury, impaired repair mechanisms, and metabolic deterioration.

Inflammation and immune activation

As oxidative and metabolic stress intensify, the liver’s immune system becomes increasingly engaged. Kupffer cells, the resident immune cells of the liver, detect danger-associated molecular patterns released from injured liver cells and respond by producing pro-inflammatory cytokines, including TNF-α, IL-6, and IL-1β.

These cytokines activate intracellular stress signaling pathways. These pathways further impair insulin signaling and reinforce mitochondrial stress, amplifying the metabolic spiral that drives MASLD progression. Persistent immune activation also influences stellate cell activation and fibrogenesis, establishing a link between metabolic dysregulation and structural liver injury.

Gut-liver axis and metabolic endotoxemia

Emerging evidence emphasizes the role of intestinal dysbiosis in the pathogenesis of MASLD. Alterations in gut microbial composition can increase intestinal permeability, allowing lipopolysaccharide (LPS) and other microbial metabolites to enter circulation. LPS activates Kupffer cells and promotes liver inflammation, amplifying the inflammatory tone already present in insulin-resistant metabolic states.

Disruptions in this axis impair liver regeneration, hinder mitochondrial recovery, and contribute to the chronicity of steatosis. Over time, impaired gut–liver communication becomes a central contributor to persistent inflammation, reduced metabolic flexibility, and progression to steatohepatitis.

Lifestyle medicine approaches to treatment

In addition to medical treatment strategies, integrative health approaches play a central role in restoring metabolic flexibility, supporting mitochondrial function, and addressing the behavioral and environmental drivers that shape the metabolic milieu in which MASLD develops.

Evidence supports dietary therapies, physical activity, weight optimization, and emerging mitochondria-targeted strategies as practical components of a comprehensive approach.

Because mitochondrial dysfunction is central to the pathogenesis of MASLD, multiple therapeutic strategies aim to restore mitochondrial function. Lifestyle interventions, including caloric restriction, exercise, and nutrient-dense diets, remain the most broadly effective and safest means of improving mitochondrial health.

Nutrition and dietary patterns

The international dietary consensus on MASLD emphasizes an overall energy-controlled, nutrient-dense pattern tailored to individual metabolic and cultural needs. Caloric reduction of approximately 500-750 kcal per day can significantly reduce liver fat, but qualitative dietary composition also matters.

Mediterranean-style diets that are rich in vegetables, fruits, whole grains, legumes, nuts, and olive oil consistently improve hepatic steatosis, insulin sensitivity, and cardiometabolic markers.

Monounsaturated fats and omega-3 fatty acids appear to shift fats away from storage and help mitigate inflammatory signaling, while polyphenols may activate antioxidant pathways to counteract oxidative stress. Conversely, diets high in added sugars make mitochondrial oxidative stress worse and accelerate steatosis.

Reducing ultra-processed foods, refined carbohydrates, and saturated fats is therefore central to decreasing toxin loads.

Fermentable fibers and plant-based diversity also support a healthier gut microbiome by enhancing short-chain fatty acid (SCFA) production, improving gut barrier integrity, and enhancing bile acid signaling. These mechanisms can directly improve liver function via the gut-liver axis.

Physical activity and movement

Regular physical activity improves MASLD through several interlocking physiologic pathways, many of which operate independently of weight loss. Exercise increases skeletal muscle glucose uptake, reduces circulating insulin levels, and improves metabolic flexibility, thereby reducing the liver’s burden of chronically absorbing excess substrates that other tissues cannot metabolize.

Aerobic training enhances mitochondrial biogenesis, improving whole-body oxidative capacity and reducing the burden of lipids that would otherwise be diverted to the liver.

Resistance training adds a unique advantage by increasing lean muscle mass, expanding the body’s metabolic ‘sink’ for glucose and fatty acids, and improving insulin sensitivity.

Several trials demonstrate meaningful reductions in steatosis with exercise alone, and this makes exercise a compelling intervention for weight loss and positions physical activity as a form of metabolic conditioning.

In conclusion

MASLD is ultimately a reflection of how our modern environment interacts with human physiology. When the metabolic load exceeds the body’s capacity to adapt, the liver becomes the first place where this imbalance becomes visible. The encouraging piece is that these pathways are not fixed. By improving mitochondrial function, reducing inflammatory burden, and supporting metabolic flexibility through nutrition and movement, we can meaningfully shift the terrain in which MASLD develops. Understanding the mechanisms behind the diagnosis gives us leverage, and with that leverage comes the opportunity to create measurable change.

If you’re living with one or more lifestyle-related chronic conditions and are ready to move beyond symptom management, I offer personalized consultations focused on physiology, labs, and upstream drivers of disease. Book a discovery appointment to explore your symptoms, review relevant biomarkers, and develop a targeted, evidence-informed plan. Start your health journey with me.

References

Dayal, U., Soni, U., Bansal, S., Aggarwal, K., Chennupati, C., Kanagala, S. G., Gupta, V., Munjal, R. S., & Jain, R. (2025). MAFLD: Exploring the systemic effects beyond liver. Journal of Community Hospital Internal Medicine Perspectives, 15(1), 42–48. https://doi.org/10.55729/2000-9666.1426

Fouad, Y., Alboraie, M., & Shiha, G. (2024). Epidemiology and diagnosis of metabolic dysfunction-associated fatty liver disease. Hepatology International, 18(Suppl 2), 827–833. https://doi.org/10.1007/s12072-024-10704-3

Hu, Y., Hu, X., Jiang, L., Luo, J., Huang, J., Sun, Y., Qiao, Y., Wu, H., Zhou, S., Li, H., Li, J., Zhou, L., & Zheng, S. (2025). Microbiome and metabolomics reveal the effect of gut microbiota on liver regeneration of fatty liver disease. EBioMedicine, 111, 105482. https://doi.org/10.1016/j.ebiom.2024.105482

Hu, Z., Yue, H., Jiang, N., & Qiao, L. (2025). Diet, oxidative stress and MAFLD: A mini review. Frontiers in Nutrition, 12, 1539578. https://doi.org/10.3389/fnut.2025.1539578

Lai, S., Tang, D., & Feng, J. (2025). Mitochondrial targeted therapies in MAFLD. Biochemical and Biophysical Research Communications, 753, 151498. https://doi.org/10.1016/j.bbrc.2025.151498

Li, X., Chen, W., Jia, Z., Xiao, Y., Shi, A., & Ma, X. (2025). Mitochondrial dysfunction as a pathogenesis and therapeutic strategy for metabolic-dysfunction-associated steatotic liver disease. International Journal of Molecular Sciences, 26(9), 4256. https://doi.org/10.3390/ijms26094256

Mantovani, A., & Dalbeni, A. (2023). NAFLD/MAFLD: New evidence. International Journal of Molecular Sciences, 24(8), 7241. https://doi.org/10.3390/ijms24087241

Pan, J., Wu, F., Chen, M., He, J., Gu, Y., Pei, L., Lai, X., Zhang, Z., & Yang, L. (2024). Prevalence of NAFLD, MAFLD, and MASLD: NHANES 1999–2018. Diabetes & Metabolism, 50(6), 101562. https://doi.org/10.1016/j.diabet.2024.101562

Peng, H. Y., Lu, C. L., Zhao, M., Huang, X. Q., Huang, S. X., Zhuo, Z. W., Liu, J., Lu, Y. P., & Lv, W. L. (2025). Clinical characteristics of MASLD/MetALD/MAFLD/NAFLD and the relative risk analysis on metabolic disorders. BMC Gastroenterology, 25(1), 372. https://doi.org/10.1186/s12876-025-03912-0

Pennisi, G., Infantino, G., Celsa, C., Di Maria, G., Enea, M., Vaccaro, M., Cannella, R., Ciccioli, C., La Mantia, C., Mantovani, A., Mercurio, F., Tilg, H., Targher, G., Di Marco, V., Cammà, C., & Petta, S. (2024). Clinical outcomes of MAFLD versus NAFLD: A meta-analysis of observational studies. Liver International, 44(11), 2939–2949. https://doi.org/10.1111/liv.16075

Xue, Y., Xu, J., Li, M., & Gao, Y. (2022). Potential screening indicators for early diagnosis of NAFLD/MAFLD and liver fibrosis: Triglyceride glucose index-related parameters. Frontiers in Endocrinology, 13, 951689. https://doi.org/10.3389/fendo.2022.951689

Zeng, X. F., Varady, K. A., Wang, X. D., Targher, G., Byrne, C. D., Tayyem, R., Latella, G., Bergheim, I., Valenzuela, R., George, J., Newberry, C., Zheng, J. S., George, E. S., Spearman, C. W., Kontogianni, M. D., Ristic-Medic, D., Peres, W. A. F., Depboylu, G. Y., Yang, W., Chen, X., … Zheng, M. H. (2024). The role of dietary modification in the prevention and management of metabolic dysfunction-associated fatty liver disease: An international multidisciplinary expert consensus. Metabolism: Clinical and Experimental, 161, 156028. https://doi.org/10.1016/j.metabol.2024.156028

Zheng, Y., Wang, S., Wu, J., & Wang, Y. (2023). Mitochondrial metabolic dysfunction and non-alcoholic fatty liver disease: New insights from pathogenic mechanisms to clinically targeted therapy. Journal of Translational Medicine, 21(1), 510. https://doi.org/10.1186/s12967-023-04367-1

Zhou, X. D., Cai, J., Targher, G., Byrne, C. D., Shapiro, M. D., Sung, K. C., Somers, V. K., Chahal, C. A. A., George, J., Chen, L. L., Zhou, Y., Zheng, M. H., & CHESS-MAFLD Consortium. (2022). Metabolic dysfunction-associated fatty liver disease and implications for cardiovascular risk and disease prevention. Cardiovascular Diabetology, 21(1), 270. https://doi.org/10.1186/s12933-022-01697